Last updated: February 22, 2026
Overview of the Drug
NDC 59762-1207 corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor used primarily in oncology. Approved by the FDA for multiple indications, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, Nivolumab has demonstrated significant clinical benefit across diverse patient populations.
Market Size and Key Drivers
Current Market Landscape
- Global Oncology Immunotherapy Market: Valued at approximately $50 billion in 2022, expected to grow at a CAGR of 11% through 2027 (Research and Markets, 2023).
- Nivolumab Sales: Generated $6.4 billion worldwide in 2022, representing a 23% year-over-year increase (IQVIA, 2023). U.S. sales account for roughly 50% of this total.
Approved Indications and Market Penetration
| Indication |
Year of Approval |
U.S. Market Share |
Notes |
| Melanoma |
2014 |
35% |
First approved indication, high unmet need |
| Non-small cell lung cancer |
2015 |
25% |
Largest indication by revenue |
| Renal cell carcinoma |
2018 |
10% |
Growing adoption, expanding indications |
| Other indications (Hodgkin lymphoma, etc.) |
2017-2022 |
10-15% |
Increasing, but smaller share |
Competitive Landscape
Key competitors include Pembrolizumab (Keytruda) and Atezolizumab (Tecentriq). Market share is shifting toward Pembrolizumab, which surpassed Nivolumab in several indications due to broader approvals and longer market presence.
| Drug |
Market Share (2022) |
Key Indications |
Price Range per 100 mg |
| Nivolumab |
40% |
Melanoma, NSCLC, RCC |
$9,500–$12,000 |
| Pembrolizumab |
45% |
Melanoma, NSCLC, MSI-H |
$10,000–$13,000 |
| Atezolizumab |
10% |
Lung, bladder cancers |
$9,000–$11,500 |
Price Projections
Current Pricing
Nivolumab’s wholesale acquisition cost (WAC) for a 100 mg dose in the U.S. averages around $10,000, with actual transaction prices often lower due to discounts and rebates. The drug is administered intravenously every 2–4 weeks, depending on the indication and treatment regimen.
Price Trends and Future Outlook
- Pricing Stability (2023-2025): Prices are expected to remain flat or decline slightly due to increased biosimilar competition and payer negotiations.
- Biosimilar Impact: No biosimilar approved for Nivolumab as of 2023, but biosimilar development is active, with several filings expected in the next 2 years.
- Reimbursement Influences: Payer pressure for cost-effective treatments may lead to discounts of 10-15% in real transaction prices over the next 3 years.
- Regulatory and Market Shifts: Expansion into early-stage cancers and new combination therapies might influence pricing strategies, potentially increasing per-treatment costs.
| Year |
Estimated Average Price per 100 mg |
Notes |
| 2023 |
$10,000 |
Current market price with discounts and rebates |
| 2024 |
$9,750 |
Slight reduction due to payer negotiations, no biosimilar impact yet |
| 2025 |
$9,500 |
Biosimilar candidates entering late-stage development, potential price pressure |
Revenue Projections
Assuming continued growth driven by expansion indications and improved pricing efficiency, Nivolumab’s global revenue could reach approximately $8.5–$9 billion by 2025.
Regulatory and Market Risks
- Biosimilar Competition: Several biosimilars are in late-stage development, with expected approvals in 2024–2025. These biosimilars could reduce market share and price.
- Patent Expiry: U.S. patents extend until 2028-2030, providing a window of market exclusivity, but legal challenges could accelerate biosimilar entry.
- Clinical Trial Outcomes: Positive results from ongoing trials for new indications could expand volume but may also lead to price adjustments based on reimbursement strategies.
- Healthcare Policy: Changes in reimbursement policies, such as value-based pricing and emphasis on cost-effectiveness, could influence future pricing.
Key Takeaways
- Nivolumab (NDC 59762-1207) remains a leading immunotherapy in oncology with high revenue and expanding indications.
- Current U.S. prices average around $10,000 per 100 mg dose, with slight declines expected as biosimilars and negotiations influence the market.
- Global revenues could grow to nearly $9 billion by 2025, driven by indication expansion and increased adoption.
- Biosimilar competition is the primary risk to sustained pricing power and market share.
- Market dynamics favor continued growth but require monitoring of regulatory approvals, clinical data, and policy shifts.
FAQs
What is the primary indication for Nivolumab?
Used mainly for melanoma, NSCLC, and renal cell carcinoma.
When is biosimilar competition expected?
Late-stage biosimilars likely to seek approval between 2024 and 2025.
How is Nivolumab priced in comparison to competitors?
Prices are similar, in the range of $9,000–$13,000 per 100 mg dose, with slight variations based on negotiation and discounts.
What factors could influence future prices?
Biosimilar entries, clinical trial results, reimbursement policies, and indication expansions.
What is the expected market share of Nivolumab in oncology immunotherapy?
Approximately 40–45% globally, though competition with Pembrolizumab approaches parity.
References
[1] Research and Markets. (2023). Global Oncology Immunotherapy Market Report.
[2] IQVIA. (2023). The Power of Data: Immunotherapy Sales Analysis.
[3] U.S. Food and Drug Administration. (2022). Approvals of Nivolumab and other immune checkpoint inhibitors.
